AbCellera Breaks Ground on Phase 2 of Global HQ in Vancouver 

Vancouver biotech anchor AbCellera has broken ground at the Mount Pleasant address that will soon be home to Phase 2 of the Vancouver-grown company’s 380,000-square-foot global headquarters. AbCellera’s leadership team were joined by members of the local biotech ecosystem to celebrate the future, world-class biotech campus that will employ hundreds of highly skilled technical personnel...READ MORE

InMed Pharmaceuticals Announces $6 Million Private Placement Priced at a Premium to Market 

InMed Pharmaceuticals Inc., a leader in the research, development and manufacturing of rare cannabinoids, announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 691,245 of its common shares at a purchase price of $8.68 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules...READ MORE

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical development company is pleased to announce that it has received approval to conduct a Phase 1 clinical study of an intravenous formulation (“IVF”) of AP-188 (“N,N-dimethyl tryptamine” or “DMT”) for the treatment of stroke in the Netherlands from the Stichting Beoordeling Ethiek Biomedisch Onderzoek, an independent Medical Research Ethics Committee. The trial will be conducted at the Centre for Human Drug Research in Leiden. DMT is a known psychedelic compound that is part of the tryptamine family...READ MORE

Lumakras® (Sotorasib) Combined with Vectibix® (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients with Kras g12c-Mutated Metastatic Colorectal Cancer

Amgen announced updated data from its Phase 1b CodeBreaK 101 study, one of the most comprehensive global clinical development programs in patients with KRAS G12C-mutated colorectal cancer. These data show that combining LUMAKRAS®/LUMYKRAS® (sotorasib) with Vectibix® (panitumumab), Amgen’s monoclonal anti-epidermal growth factor receptor (anti-EGFR) antibody, demonstrated encouraging efficacy and safety. Overall, the confirmed objective response rate was 30% in patients with chemo-refractory metastatic colorectal cancer...READ MORE

NervGen Pharma Announces Appointment of Dr. Matvey Lukashev as Vice President, Research and Preclinical Development 

NervGen Pharma Corp., a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, is pleased to announce the appointment of Matvey Lukashev, PhD, as the Company’s Vice President, Research and Preclinical Development...READ MORE

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer Inc.and BioNTech SE announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 Vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 15/15 µg) has been recommended for conditional marketing authorization by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for individuals ages 12 years and older. The European Commission will review the CHMP recommendation and is expected to make a final decision soon...READ MORE

Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress 

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors. The presentation, entitled “Preliminary Results From a Phase 1 Study Using the Bispecific, Human Epidermal Growth Factor 2 (HER2)-targeting Antibody-drug Conjugate zanidatamab zovodotin (ZW49) in Solid Cancers”, was presented by Komal Jhaveri, MD, FACP, medical oncologist...READ MORE

BME Microcredential – Project Management for Biomedical Devices

This fall, UVic Biomedical Engineering, in partnership with UVic’s Gustavson School of Business and UBC’s School of Biomedical Engineering, is pleased to offer a micro-credential on Project Management for Biomedical Device Development...READ MORE

UBC’s Engineering Mentoring Program – Now Recruiting!

UBC is currently recruiting mentors for the 2022/23 UBC Engineering Mentoring Program! For approximately one hour per month, share your knowledge and experience with students who are defining their careers, expanding their professional networks, and developing important professional skills...READ MORE

Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers...READ MORE

Roche Canada Pharma Welcomes Brigitte Nolet, President and CEO.

Roche Canada is thrilled to welcome Brigitte Nolet as President and CEO for Roche Canada Pharma. As a Canadian citizen who hails from Welland, Ontario, Brigitte has held a number of progressive leadership roles within Roche, locally and globally, since joining the company in 2006...READ MORE

Specialist Robots Kill Germs at Fraser Health

Fraser Health’s fleet of 16 Ultraviolet Germicidal Irradiation (UVGI) robots now have UVGI ‘helpers’. Two new UVGI disinfection pods have joined the team. The robots and pods are deployed at hospitals across the region to kill viruses and bacteria that linger on surfaces and can potentially cause infection…READ MORE

Life Science Analytics Global Market to Reach $37.86 Billion by 2026

The global life science analytics market is expected to grow from $21.16 billion in 2021 to $24.09 billion in 2022 at a compound annual growth rate of 13.8%. The life science analytics market is expected to grow to $37.86 billion in 2026 at a CAGR of 12%…READ MORE

Life Sciences BC Announces Incoming Board of Directors

Life Sciences BC is pleased to announce new and returning members to the Board of Directors, following its Annual General Meeting held on September 15th, 2022. The incoming Board of Directors is comprised of leaders within British Columbia’s life sciences community, all of whom are aligned with LSBC’s vision and mission of creating a provincial ecosystem where life sciences and health organizations thrive, while advocating for and promoting the growth of the province’s world-class life sciences industry…READ MORE

Associate / Scientist, Synthetic Chemistry 

The ideal candidate has experience with total synthesis or medicinal chemistry. Work with radioactivity will not be required at this position, but we offer the successful candidate the opportunity to learn to work safely with radioactive substances and learn the skills to advance targeted radiotherapies. The successful candidate will develop as a pharmaceutical scientist and help build a new company promoting Canadian radiopharmaceutical development.

This is applicable to all employment practices within our organization, including hiring, recruiting, promotion, termination, layoff, recall, leave of absence, compensation, benefits, training, and apprenticeship.

LEARN MORE

Project Manager

AbCellera is a young, energetic, and rapidly growing biotech company with an amazing team that searches, decodes, and analyzes natural immune systems to find antibodies that can be developed into drugs to prevent and treat disease. We’re looking for an experienced Project Manager to lead a portfolio of projects that span our tech stack, from discovery to pre-clinical and clinical development. The successful candidate will work with our scientists, partners and collaborators to push the frontiers of science as we expand our tech stack and solve challenging problems in biology.

LEARN MORE

QA Specialist 

Evonik’s Vancouver business operations is a development partner to the world’s pharmaceutical companies for parenteral lipid nanoparticle drug products. As an enabling contract development manufacturing organization (CDMO) partner, we offer drug formulation design, process development, scale-up, and clinical production.

LEARN MORE

Novacom Building Partners are a full service General Contracting and Construction Management build partner with a focus on biotech lab and corporate office construction. They utilize innovative construction management software paired with 3D Building Information Modeling to assist growing Life Science firms in B.C to construct or renovate their labs and corporate office spaces.

Visit Website

MYND Life Sciences Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to its Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on historic research and development that commenced in 2016 regarding the modulation of a specific gene using neuro agents such as psychedelics and other compounds. Research and development aree currently being performed.

Visit Website